Welcome to our dedicated page for HNSA news (Ticker: HNSA), a resource for investors and traders seeking the latest updates and insights on HNSA stock.
Hansa Biopharma AB (HNSA) news covers developments at a commercial-stage biopharmaceutical company focused on rare immunological conditions. Based in Lund, Sweden, with operations in Europe and the U.S., Hansa Biopharma reports on progress across its proprietary IgG-cleaving enzyme technology platform, including transplantation, autoimmune diseases and gene therapy applications.
News for HNSA frequently highlights clinical and regulatory milestones for imlifidase, a first-in-class IgG antibody-cleaving enzyme therapy that has been shown to enable kidney transplantation in highly sensitized patients. Updates include data from the pivotal U.S. Phase 3 ConfIdeS trial in kidney transplantation, long-term follow-up analyses of imlifidase-enabled transplants, and the company’s submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for desensitization of highly sensitized adult patients undergoing deceased donor kidney transplantation.
Investors following HNSA news can also expect information on IDEFIRIX product performance in approved markets, progress of next-generation asset HNSA-5487, and updates from gene therapy-related studies where imlifidase is used to reduce anti-AAV antibodies. Company announcements regularly cover participation in scientific congresses, virtual scientific and investor events, and corporate developments such as executive appointments and financing transactions.
This news feed provides a centralized view of Hansa Biopharma’s disclosures on its clinical programs, regulatory interactions, commercial activities and strategic initiatives linked to its IgG-cleaving enzyme platform. Readers interested in HNSA stock and the company’s role in rare immunological conditions can use this page to monitor key trial readouts, regulatory milestones and other material company updates over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will release its interim report for January-March 2023 on April 20, 2023, at 8:00 CET. Following the report, a telephone conference hosted by CEO Søren Tulstrup and CFO Donato Spota will take place at 14:00 CET (8:00 AM EST) to discuss the results and provide a business update. Interested participants can access the call using the provided dial-in numbers from Sweden, the UK, and the US. The presentation slides will be available on the company's website during the call and online afterward. Key upcoming financial events include the Redeye Investor Forum and the Half-year report on July 20, 2023. For more information, contact Klaus Sindahl or Stephanie Kenney.